TCR-MHC/Peptide Interaction: Prospects for New Anti-tumoral Agents

Cancer Genomics - Proteomics

GEORG TIEFENTHALER¹  ULRICH H. WEIDLE¹  GUY GEORGES¹ 

[1] Roche Pharma Research and Early Development (pRED), Roche Innovation Center Penzberg, Roche Diagnostics GmbH, Penzberg, GermanyRoche Pharma Research and Early Development (pRED), Roche Innovation Center Penzberg, Roche Diagnostics GmbH, Penzberg, GermanyRoche Pharma Research and Early Development (pRED), Roche Innovation Center Penzberg, Roche Diagnostics GmbH, Penzberg, Germany

关键词: Antibody-MHC fusion proteins;    chimeric antigen receptors;    immunological synapse;    T-cell receptor;    T-cell receptor-based fusion proteins;    review;   

DOI  :  

来源: Delinasios GJ CO

【 摘 要 】

Tumor-related antigens can be presented as peptides forming complexes with major histocompatibility complex (MHC) molecules that interact with T-cell receptors, thus generating an immunologic anti-tumor response. Unfortunately, however, this response can be decreased by many effectors and pathways. On the other hand, such peptide-MHC complexes are unique starting points for therapeutic intervention. We present strategies for eliciting an anti-tumoral response by T-cell receptor-based fusion proteins with interleukin (IL)2 and antibody constant region domains, superantigens, and T-cell recruiting antibodies, as well as using genetically modified autologous T-cells as effectors. Another strategy is to direct peptide-MHC complexes to tumors as fusion proteins with an antibody-derived targeting moiety. Finally, we describe T-cell receptor-mimicking antibodies and antibody conjugates as anti tumoral agents.

【 授权许可】

Unknown